Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Published Online: 2012-05-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Caicun Zhou•Dae Seog Heo•Eng-Huat Tan•Jacques Cadranel•James Chih-Hsin Yang•Keunchil Park•Lucio Crino•Mehdi Shahidi•Mengzhao Wang•Robert M Lorence•Sang-We Kim•Tsu-Yi Chao•Vera Hirsh•Vincent A Miller•Wu-Chou Su•Xiuyu Julie Cong•Yan Sun•Yuh-Min Chen
